GlassScriptPhysician profile
Robert S Hall
NPI 1922506583
$4,058.78
in general payments reported to CMS, 2019-2025
35 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical General Practice (Registered Nurse) provider received nationally (typical 2025 total: $110).
See the full distribution for General Practice (Registered Nurse)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,265 · 2022: $743 · 2023: $1,025 · 2024: $696 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,051.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.00 | 2021-2025 | |
| Pfizer INC. | $553.09 | 2021-2025 | |
| Novo Nordisk INC | $402.15 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $299.38 | 2021-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $263.93 | 2021-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $196.62 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $118.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $115.50 | 2022 | |
| Glaxosmithkline, LLC. | $111.96 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $99.09 | 2021 | |
| Astellas Pharma US INC | $69.99 | 2023-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $62.63 | 2022 | |
| Esperion Therapeutics, INC. | $61.74 | 2021 | |
| Optinose US, INC. | $61.62 | 2021-2023 | |
| Exact Sciences Corporation | $57.84 | 2023-2025 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $52.41 | 2023 | Quviviq |
| Boston Scientific Corporation | $50.82 | 2022-2025 | Watchman Flx, Watchman Access System |
| Jazz Pharmaceuticals INC. | $39.94 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $37.95 | 2025 | Neffy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.74 | 2023 | Xifaxan |
| Corium, LLC | $36.18 | 2022-2023 | Azstarys |
| Amgen INC. | $34.15 | 2023-2024 | Krystexxa, Otezla |
| Adlon Therapeutics L.P. | $31.67 | 2021 | |
| Seqirus USA INC | $28.50 | 2024 | Flucelvax, Fluad |
| Pharming Healthcare, INC. | $27.54 | 2023 | Ruconest |
| Eisai INC. | $26.08 | 2021 | |
| Merck Sharp & Dohme LLC | $19.22 | 2022 | |
| Shield Therapeutics INC | $18.80 | 2023 | Accrufer |
| Medtronic, INC. | $18.19 | 2025 | Interstim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.05 | 2024 | |
| Tris Pharma INC | $15.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.11 | 2023 | Xarelto |
| Sanofi Pasteur INC. | $14.85 | 2023 | |
| Horizon Therapeutics Plc | $13.51 | 2021 | |
| Tolmar, INC. | $13.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.